“…The Shh signaling pathway is a major regulator of various processes, including cell differentiation and proliferation, and tissue polarity [ 2 , 5 ]. Inhibition of Shh signaling is widely researched because aberrant Shh signaling is a hallmark of many cancers [ 6 , 7 , 8 ], including prostate, gallbladder, pancreatic, and basal cell carcinoma [ 9 , 10 , 11 , 12 ]. Basal cell carcinoma (BCC) is the most common human cancer and is driven predominantly by the hyperactivation of the Hh pathway [ 13 , 14 , 15 ].…”